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Abstract 
A serum-free medium conditioned by U937, a human cell line of monocyte/macrophage origin, was found capable of inducing apoptosis on 
exponentially growing U937 cells themselves (autocrine suicide). The apoptosis-inducing agent is a macromolecule and possibly a protein (SKT 
factor), with a relative molecular mass in the range of 18-25 kDa. All human tumor cell lines examined have been induced to apoptosis with high 
efficiency, whereas non transformed human lymphocytes and monocytes are insensitive to the apoptosis-inducing activity; moreover, partially 
differentiated U937 are not killed but induced to full maturation. These observations uggest hat the SKT factor could possibly be a cytokine with 
a specific cytotoxic tropism, that resembles in many respects the cytokine tumor necrosis factor (TNF), even though no TNF is detectable in the 
conditioned medium. 
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1. Introduction 
Cell killing by protein factors has long been described, 
and concerns unwanted cells within the organism, such 
as transformed or exogenous cells. Cell killing can be 
achieved by damaging the target cells, as in the case of 
perform, a protein that aspecifically produces channels 
in the plasma membrane, leading to necrosis [l]. How- 
ever, a more precisely ‘targeted’ mode of cell killing can 
be achieved by the acting proteins throughout the stimu- 
lation of specific receptors on the target cells, that are 
thus induced to commit suicide [2]. In these instances cell 
death is the result of a cross-talk between cells, and the 
mode of cell death is almost invariably apoptosis [3]. 
Indeed apoptotic cell death avoids the inflammation 
process that always accompanies necrosis [4], and is 
characteristic of ‘physiological’, programmed, cell death 
[5-81. The proteins involved in this type of cell killing are 
functionally cytokines [9]; the better studied example is 
the tumor necrosis factor (TNF) [lO--131, which induces 
apoptosis preferentially on tumor cells which possess the 
specific receptors (TNFr) [l&16], through mechanisms 
that have not been completely elucidated so far [17]. 
TNFrs belong to a family of integral membrane proteins 
that are able to transduce a signal of suicide once specif- 
ically activated, that include also the Apo-I and the Fas 
antigen [18-211 (indeed, they have been shown to be 
identical [22]). Also the receptor for nerve growth factor 
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belongs to the same family, even though it has an anti- 
thetic role, since it protects cells from apoptosis [23]. 
Interestingly, TNF itself can induce cell proliferation (as 
opposed to cell killing) on non-transformed fibroblasts 
[24] and other cell types [25], and can also act as a differ- 
entiating agent [26-281, depending on the target cells. 
Indeed, the messages brought about by these cytokines, 
viewed in the context of the whole organism, are appar- 
antly ambiguous, since the same message can induce 
proliferation, differentiation or apoptosis. We describe 
here the first observations about a novel factor, possibly 
a protein, that is indeed capable of exerting either a 
differentiative or an apoptosis-inducing action depend- 
ing on the target cells. 
2. Materials and methods 
2.1. Cell culture and treatments 
U937 cells were kindly provided by Dr. E. D’Ambrosio, Dip. 
Medicina Sperimentale, C.N.R., Roma. All the cells were cultured in 
RPM1 medium supplemented with 2 mM L-glutamine, 100 II-l/ml pen- 
icillin and streptomycin and 10% FCS (unless otherwise indicated), and 
kept in a controlled atmosphere (5% CO& incubator at 37°C. 
Apoptotic activity inhibition treatment: cells in conditioned medium 
have been treated with the following chemicals: Cycloheximide, 10 
&ml; 3-aminobenzamide, 5 mM; PMSF, 1 mM. 
Differentiation inducing treatment: cells were incubated for 48 h with 
the following compounds: 1.2 mM Dimethylsulfoxide (DMSO); 0.5 PM 
12-O-tetradecanoylphorbol 13-acetate (TPA); 10 mM butyric acid; or 
have been kept in alkaline medium (pH 8-8.5) for 48 h. When appropri- 
ated (see section 3), the partially differentiated stage (pseudo-monocyte 
stage) has been controlled by the ability to reduce NitroBlue-tetra- 
zolium (NBT) [29], whereas in the fully differentiated stage (pseudo- 
macrophage) this characteristic is suddenly lost, and the emission of 
0014-5793/94/$7.00 0 1994 Federation f European Biochemical Societies. All rights reserved. 
SSDZ 0014-5793(94)00287-6 
36 L. Ghibelli et al. IFEBS Letters 344 (1994) 35-40 
pseudopodes i observed and attachment to the substrate of the culture 
flask [30]. 
2.2. Analysis of apoptosis 
Apoptosis was characterized by DNA fragmentation to give a ladder- 
like pattern, and nuclear fragmentation in several smaller fragments, 
ranging in number from 2 up to > 20 per cell, detectable by optical 
microscopy on slides of hematossilyn-stained cells. 
Preparation and staining of slides: 2 x 10’ cells, fixed in 4% parafor- 
maldeide, were loaded on a gelatinized slide, stained with hematoxylin, 
and analyzed for direct optical microscopy. 
Analysis of DNA: lo6 cells were lysed in a buffer containing 10 mM 
EDTA, 100 mM Tris pH 80.5% sodium lauroyl sarkosine, 200 pg/ml 
proteinase K. Nucleic acids were extracted by phenol-(chloroform/ 
isoamylic alcohol 24:1), ethanol precipitated, incubated in 100 &ml 
RNase A 60 min at 37°C. The ourified DNA is loaded on a 1.5% 
agarose gel in TAE buffer, stained with 10 &ml ethydium bromide, 
and visualyzed on a 254 nM UV transilluminator. 
Quantification of apoptosis: the fraction of cells with a fragmented 
nucleus among the total cell population, was calculated on the hema- 
toxylin-stained slides, counting at least 100 cells in at least 3 random 
selected fields (a comparison with cytofluorimetric analysis is to be 
described elsewhere). 
2.3. Conditioned medium fractionation and activity assay 
To foetal calf serum-containing conditioned medium was added 
(NH&SO,. The resulting precipitates at 20,40,60 and 80% (NH&SO, 
were collected by centrifugation, dissolved in a small volume of phos- 
phate-buffered saline (PBS) and dialyzed against serum-free medium. 
The activity assay has been performed by calculating the fraction of 
apoptotic cells (see above) after 4 and 18 h of incubation of exponen- 
tially growing cells in the dialyzed fractions. 
Serum-free conditioned medium was gel-filtered on a Sephadex G- 
100 column (1.6 x 30 cm) with 0.3 M NH,HCO,. In order to test the 
SKT factor activity, chromatographic fractions were collected, lyophil- 
ized, dissolved in serum free medium, and pools of four contiguous 
fraction were applied on exponentially growing U937. The activity 
assay has been performed by calculating the fraction of apoptotic cells 
(see above) after 4 and 18 h of incubation. 
2.4. TNF detection 
U937 conditioned medium was assayed for TNFa with an ELISA 
assay, by a commercially available kit with a detection limit of 25 pg/ml. 
3. Results 
3.1. Induction to apoptosis by conditioned medium 
Under several circumstances (which we are still ana- 
lyzing) U937 cells respond by undergoing an as yet ‘un- 
explainable’ apoptosis (Fig. 1): in these instances they 
condition the culture medium which, independently of 
the presence of FCS, can induce exponentially growing 
U937 to apoptosis. Fig. 2 shows the characteristics of 
apoptotic (vs. normal) U937, that is: nuclear fragmenta- 
tion (Fig. 2a), and DNA fragmentation in a ladder-like 
pattern (Fig. 2b). Fig. 3 describes the kinetics of the 
induction to apoptosis by U937-conditioned medium, 
obtained by calculating the fraction of cells with apop- 
totic morphology (see Fig. 2a) among the total cell pop- 
ulation (see section 2). The presence of two separate 
peaks, observed in all the experiments performed, has 
been confirmed by cytofluorimetric analysis (to be de- 
scribed elsewhere), and is characteristic of the apoptosis 
induced by this conditioned medium. Indeed, in the case 
described here, U937 that undergo apoptosis during the 
Fig. 1. Serum-free growth curve of U937, following treatment as to 
produce apoptosis-inducing activity. 
first wave are rapidly removed from the culture, whereas 
in the case of apoptosis induced by other agents (i.e. 
stress conditions) the apoptotic cells do not disappear 
from the culture, and can thus accumulate in the medium 
[311. 
The two peaks should be the result of the same induc- 
ing agent, since they have been obtained even with par- 
tially fractionated conditioned medium (see below); how- 
ever, we cannot exclude that more than one apoptotic 
inducing activity with different effects is present in the 
conditioned medium. 
3.2. The apoptosis-inducing activity is a macromolecule 
and possibly a protein 
We observed that the activity is maintained after dial- 
ysis against serum-free medium, showing that the agent 
is a macromolecule. Moreover, it is precipitable by am- 
monium sulphate (AS); indeed upon AS fractionation, 
only a slight activity was present in the fractions precip- 
itated at concentrations below 80%, while 100% induc- 
tion to apoptosis was obtained with the protein fractions 
precipitated with 80% AS. This suggests that the apopto- 
sis inducing activity is a protein, that we have called the 
SKT factor, since other possible effector macromolecules 
(i.e. sugars or lipids) are not precipitable by AS [32]. 
We have performed a preliminary purification of the 
SKT factor activity from serum-free conditioned me- 
dium by gel permeation chromatography over a G-100 
Sephadex column. The two experiments performed have 
shown that the apoptosis-inducing activity is eluted in a 
range of relative molecular mass of about 18-25 kDa, 
and is confined to a few adjacent fractions (among 80 
collected) that give 100% induction to apoptosis, 
whereas all the other fractions give background values 
(Fig. 4) 
3.3. Effect of conditioned medium on various cell types 
and differentiative stages 
We observed that all of the four human tumor cell 
lines tested so far were induced to apoptosis by the con- 
ditioned medium containing the SKT factor (Table 1). 
Also freshly explanted human monocytes (HM), still in- 
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Fig. 2. Characteristics of apoptotic U937, as appear after 4 h incubation in conditioned medium. (A) Morphology of apoptotic cells (arrows), with 
highly fragmented nuclei; and normal, viable U937. (B) DNA analysis of apoptotic (1) and viable (2) U937, showing the characteristic DNA 
fragmentation of apoptotic cells. 
differentiated, are induced to apoptosis. Instead, once 
differentiated by the cytokine macrophage-colony stimu- 
lating factor (M-CSF), HM lost sensitivity and survived 
the treatment (Table 1). Interestingly, also the sensitivity 
of U937 cells to the cytotoxic activity of SKT can be 
modulated by the differentiative state of the cells. 
U937 were shown to be induced to differentiate by 
several treatments, to give slightly different differenti- 
ated states [30]. We have used three known differentia- 
tive agents: dimethylsulfoxide (DMSO); 12-O-tetrade- 
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Fig. 3. Kinetics of the induction to apoptosis by U937conditioned 
medium on exponentially growing U937 cells (one of several experi- 
ments is shown). 
canoylphorbol 13-acetate (TPA); butyric acid; and a 
novel differentiation-inducing treatment, that is the incu- 
bation of exponentially growing U937 in alkaline me- 
dium (pH S-8.5) for 48 h (to be described elsewhere). 
TPA, butyric acid, and alkaline medium, all induce on 
U937 the ability to reduce NBT, a known marker of the 
monocytic differentiative stage (see section 2) though 
the induced cells did not look alike (i.e. TPA induces 
terminal differentiation with the emission of pseudo- 
pods; DMSO induce a slight different cell morphology 
and not the ability of reducing NBT), suggesting that the 
different treatments end up with different differentiated 
states. 
Table 2 shows that the apoptosis-inducing activity of 
SKT, on U937 induced to differentiate by ‘different 
agents, is strongly reduced in three out of four treat- 
ments. 
Moreover, upon differentiation induced by alkaline 
medium, SKT cytotoxic activity is converted into an 
activity capable of inducing full maturation: alkaline me- 
dium-treated rounded, floating, NBT positive U937, 
upon incubation with the SKT factor become attached 
to the substrate, show pseudopods, and have lost the 
capacity of reducing NBT, all characteristics of differen- 
tiated macrophages. 
3.4. Functional analysis of the SKT factor 
In order to gain an insight in the mechanism of action 
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Fig. 4. Gel filtration of U937conditioned medium. Protein profile and 
apoptosis-inducing activity after G-100 Sephadex column filtration 
(one of two independent experiments is shown). 
of the SKT factor, we tried to block its apoptosis-induc- 
ing activity. For this purpose, we tested the action of 
compounds that are known to block or inhibit apoptosis 
induced by other means, by treating exponentially grow- 
ing cells before and during incubation in the conditioned 
medium. The protein synthesis inhibitor cicloheximide 
(CHX), and the poly-ADP-ribosyl-transferase inhibitor, 
3-aminobenzamide (3-ABA), both shown to inhibit some 
forms of apoptosis [31,33-361, did not have any effect on 
blocking the apoptosis-inducing activity of the SKT fac- 
tor, nor did the Ca2’ ion-chelating agent EGTA. Instead, 
we could block it by using the protease inhibitor PMSF. 
This is in line with several findings describing cytotoxic 
proteins with site-specific protease activity [37,38]. How- 
ever, this does not necessarily mean that the SKT factor 
is in itself a protease, but rather that a protease is likely 
to be necessary in the chain of events leading to the 
induction to apoptosis (indeed PMSF can enter inside 
the cells): it is known that the apoptosis-inducing activity 
of TNF is sensitive to the use of protease inhibitors, even 
though TNF does not have any protease activity [39]. 
The SKT factor and TNF indeed share also other 
characteristics: they are produced by the same cell types, 
have a similar molecular weight [40] and similar specific 
cytotoxicity, and can induce differentiation or apoptosis 
depending on the target cells [41]; however, they are not 
the same molecule, for the following reasons. First, no 
TNF was detectable in the conditioned medium by 
ELISA; second, the kinetics of induction to apoptosis by 
TNF is much slower than the SKT’s (indeed we began 
to detect it at 18 h post-incubation, not shown); third, the 
Epstain-Barr virus positive (EBV+) lymphoma Raji, in- 
sensitive to the cytotoxic effect of TNF (indeed they lack 
the TNF receptor) [42], are induced to apoptosis by the 
SKT factor (see Table 1); fourth, TNF is recovered as a 
40-45 kDa trimer from gel filtration [10,43], whereas the 
profile of SKT elution shows that the cytotoxic activity 
is eluted as a smaller molecule (Fig. 4). 
4. Discussion 
The data presented here suggest that the SKT factor, 
capable of inducing apoptosis on tumor cells, is a pro- 
tein, and is produced by the human cell line of monocytic 
origin U937. Indeed, it is not the result of an alteration 
of a seric protein, since it is present even in serum-free 
conditioned medium. Other cytotoxic factors, of mon- 
ocyte/macrophage or lymphocyte origin, can induce ap- 
optosis on target cells, such as leukoregulin [44] and a 
serine esterase [37], released by cytotoxic T lymphocytes, 
fragmentin, released by natural killer cells [45], an argi- 
nase released by macrophages [38], TNFa, TNFB (also 
known as lymphotoxin) [ 11,461. However, the SKT fac- 
tor differs from any of these proteins either by mode of 
action or molecular weight (i.e. all the isoformes of the 
macrophages-differentiating CSF- 1 cytokine are larger 
than SKT), so that we can exclude that they are identical 
to SKT. Moreover, we can also exclude identity to TNF 
(see section 3) even if its characteristics look very similar 
to those of SKT. Many cytokines, known for different 
properties, such as interferon y [47], can act as cytotoxic 
effecters in some instances; we are analyzing whether the 
SKT factor could be an already known cytokine, al- 
though a behaviour such as that described for SKT has 
not been described so far; this leads us to believe this 
could be a novel factor. Alternatively, it could arise from 
the specific proteolysis of a cytokine that could be non- 
cytotoxic in the native state, to give a product of homog- 
enous size. The Fas-antigen, which exerts an apoptosis- 
inducing function similar to TNFr’s, responds to the 
stimulation of a ligand that has not yet been identified, 
though its excistance has been inferred by genetic analy- 
sis of the gld murine lymphoproliferative pathology [48]. 
Table 1 
Sensitivity to the cytotoxic activity of SKT factor. Analysis on various cell types and cell lines 
SKT sensitive cells SKT non-sensitive cells 
Ramos (human lymphoma, EBV-) Human quiescent blood lymphocytes 
Raji (human lymphoma, EBV’) Human monocytes, differentiated with M-CSF 
HeLa (human epithelial tumor cell line) U937, differentiated 
U937 (human monocytes tumor cell line), undifferentiated 
Human monocytes, undifferentiated 
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Table 2 
Quantification of apoptosis by the SKT factor on U937 induced to 
differentiation 
Acknowledgements: We wish to thank Prof. LG. Spagnoli for helpful 
discussions and suggestions; C.N. is a recipient of a fellowship from 
Montedison. 
C Alkaline DMSO TPA 
medium 1.2 mM 0.5 PM 
Butyric 
acid 
10 mM 
References 
Fresh medium 
Conditioned 
1 12 9 25 4 
medium (18 h) 63 8* 21 37 100 
The values indicate the fraction of apoptotic cells at the end of each 
treatment (see section 2). All differentiating treatments lasted 48 h, then 
differentiated cells were incubated with either fresh or conditioned 
medium for a further 18 h. 
*All viable cells look terminally differentiated (see section 2). 
It would sound appealing that the ligand of the Fas 
antigen would be the SKT factor, since the mode, speci- 
ficity, and kinetics of SKT cytotoxic activity are very 
similar to those induced by the anti-Fas antibody on Fas 
antigen-bearing cells. 
SKT’s selective behaviour, that is induction to apopto- 
sis on indifferentiated cells, induction to full maturation 
on partially differentiated cells, recalls the specific cyto- 
toxicity TNF exerts on tumor vs. normal cells. What 
could be the reason for this different cell response? In the 
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cycloheximide become sensitive to the cytotoxic action 
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U937 system the induction to differentiation, usually as- 
sociated to the loss of the malignant phenotype, could be 
paralleled by the reappearance of a factor present in 
normal, differentiated monocytes/macrophages, that 
could turn the SKT cytotoxic signal into a physiological 
maturation signal. 
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